Island Pharmaceuticals Ltd (ILA) - Total Assets
Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) holds total assets worth AU$7.49 Million AUD (≈ $5.30 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Island Pharmaceuticals Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Island Pharmaceuticals Ltd for the company's overall valuation and market capitalisation.
Island Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Island Pharmaceuticals Ltd's total assets of AU$7.49 Million consist of 100.0% current assets and 0.0% non-current assets. Review Island Pharmaceuticals Ltd total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 96.8% |
| Accounts Receivable | AU$179.61K | 2.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Island Pharmaceuticals Ltd share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Island Pharmaceuticals Ltd's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 96.8% of total assets in 2024, up from 5.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 2.4% of total assets.
Island Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Island Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Island Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.27 | 2.45 | 0.03 |
| Quick Ratio | 22.27 | 3.29 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$7.16 Million | AU$1.52 Million | AU$-657.00 |
Island Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Island Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.79 |
| Latest Market Cap to Assets Ratio | 10.59 |
| Asset Growth Rate (YoY) | 192.2% |
| Total Assets | AU$7.49 Million |
| Market Capitalization | $79.39 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Island Pharmaceuticals Ltd's assets at a significant premium (10.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Island Pharmaceuticals Ltd's assets grew by 192.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Island Pharmaceuticals Ltd (2019–2024)
The table below shows the annual total assets of Island Pharmaceuticals Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$7.49 Million ≈ $5.30 Million |
+192.19% |
| 2023-12-31 | AU$2.56 Million ≈ $1.81 Million |
+25.14% |
| 2022-12-31 | AU$2.05 Million ≈ $1.45 Million |
-58.17% |
| 2021-12-31 | AU$4.90 Million ≈ $3.47 Million |
-26.18% |
| 2020-12-31 | AU$6.64 Million ≈ $4.70 Million |
+39034664.71% |
| 2019-12-31 | AU$17.00 ≈ $12.03 |
-- |
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more